NCT04131738View on ClinicalTrials.gov

Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 7, 2020

Primary Completion Date

November 30, 2021

Study Completion Date

August 17, 2022

Conditions
Graft-versus-host-diseaseGraft Vs Host Disease
Interventions
DRUG

Baricitinib

Baricitinib may be taken without regard to food. It should be taken at the same time every day.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT04131738 - Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation | Biotech Hunter | Biotech Hunter